Avaliação da eficácia e tolerabilidade do ômega 3 e ácido fólico no tratamento de pacientes com zumbino

Abstract

The objective of this study was to evaluate the use of omega 3 in association with folic acid for the treatment of sensorineural hearing loss. For this purpose, 15 patients aged between 18 and 75 years were included in the study. The participating patients received orally a single daily dose of 5 mg of folic acid and 2 g dose of omega 3 (eicosapentaenoic fatty acid (EPA) - 360 mg and docosahexaenoic acid (DHA) - 240 mg), three times a day for a period of 3 months (Rexall Sundown, Inc. ) and were followed over 16 weeks. The Tinnitus Handicap Inventory (THI), and The Clinical Global Impression Scale-Improvement (CGI-I) were used as a method of assessing results. Of the 15 patients included in the study, none withdrew consent or were excluded during the process. No patient reported any adverse event. There was a reduction, on average, of 14.2 units in THI, which corresponds to a 35% drop from baseline value (p- value <0.001). Considering the results obtained by the CGI-I, improvements were observed in 80% of the patients and no worsening were reported. It was concluded that the experimental treatment is safe, highly tolerable and with considerable improvement rates, opening doors to new possibilities in managing patients with tinnitus.